羟氯喹和阿奇霉素对新型冠状病毒肺炎患者严重急性呼吸综合征冠状病毒2清除率的影响：一项荟萃分析 - Suppr

Suppr

超能文献

Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.

作者信息

Million Matthieu, Roussel Yanis, Gautret Philippe, Raoult Didier

机构信息

IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France.

IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, VITROME, Marseille, France.

出版信息

Int J Antimicrob Agents. 2021 Jan;57(1):106240. doi: 10.1016/j.ijantimicag.2020.106240.

DOI:10.1016/j.ijantimicag.2020.106240

PMID:33408019

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7779266/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb17/7779266/b0a89c3dcea8/gr1_lrg.jpg

相似文献

Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.

Int J Antimicrob Agents. 2021 Jan;57(1):106240. doi: 10.1016/j.ijantimicag.2020.106240.

Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.

Int J Antimicrob Agents. 2021 Jan;57(1):106238. doi: 10.1016/j.ijantimicag.2020.106238.

Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.

Int J Antimicrob Agents. 2021 Jan;57(1):106239. doi: 10.1016/j.ijantimicag.2020.106239.

Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.

Int J Antimicrob Agents. 2021 Jan;57(1):106242. doi: 10.1016/j.ijantimicag.2020.106242.

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.

Int J Antimicrob Agents. 2021 Jan;57(1):106243. doi: 10.1016/j.ijantimicag.2020.106243.

Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.

Int J Antimicrob Agents. 2021 Jan;57(1):106169. doi: 10.1016/j.ijantimicag.2020.106169.

Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.

Int J Antimicrob Agents. 2021 Jan;57(1):106172. doi: 10.1016/j.ijantimicag.2020.106172.

Advanced statistical methods and designs for clinical trials for COVID-19.

Int J Antimicrob Agents. 2021 Jan;57(1):106167. doi: 10.1016/j.ijantimicag.2020.106167.

Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.

Int J Antimicrob Agents. 2021 Jan;57(1):106236. doi: 10.1016/j.ijantimicag.2020.106236.

Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.

Int J Antimicrob Agents. 2021 Jan;57(1):106174. doi: 10.1016/j.ijantimicag.2020.106174.

引用本文的文献

The Clinical Course and Outcomes of Patients Hospitalized Due to COVID-19 during Three Pandemic Waves in Poland: A Single Center Observational Study.

J Clin Med. 2022 Dec 13;11(24):7386. doi: 10.3390/jcm11247386.

Evaluation of clinical and laboratory characteristics and factors affecting mortality in 500 hospitalized COVID-19 patients: A retrospective study.

Saudi Med J. 2022 Nov;43(11):1254-1259. doi: 10.15537/smj.2022.43.11.20220641.

Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy.

J Clin Med. 2022 Oct 18;11(20):6138. doi: 10.3390/jcm11206138.

Consumption Trends of Antibiotics in Brazil During the COVID-19 Pandemic.

Front Pharmacol. 2022 Mar 21;13:844818. doi: 10.3389/fphar.2022.844818. eCollection 2022.

A Peek into Pandora's Box: COVID-19 and Neurodegeneration.

Brain Sci. 2022 Jan 30;12(2):190. doi: 10.3390/brainsci12020190.

Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway.

Expert Opin Pharmacother. 2021 Jun;22(8):947-952. doi: 10.1080/14656566.2021.1897104. Epub 2021 Mar 11.

Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann.

Int J Antimicrob Agents. 2021 Mar;57(3):106306. doi: 10.1016/j.ijantimicag.2021.106306. Epub 2021 Feb 14.

Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.

Int J Antimicrob Agents. 2021 Jan;57(1):106238. doi: 10.1016/j.ijantimicag.2020.106238.

本文引用的文献

Can we use hydroxychloroquine to treat COVID-19 now?

Int J Antimicrob Agents. 2021 Jan;57(1):106173. doi: 10.1016/j.ijantimicag.2020.106173.

Interferon-α2b Treatment for COVID-19.

Front Immunol. 2020 May 15;11:1061. doi: 10.3389/fimmu.2020.01061. eCollection 2020.

[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. doi: 10.3785/j.issn.1008-9292.2020.03.03.

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.

Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.

Randomized, controlled trials, observational studies, and the hierarchy of research designs.

N Engl J Med. 2000 Jun 22;342(25):1887-92. doi: 10.1056/NEJM200006223422507.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验